Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Singulair joins the fray

This article was originally published in The Tan Sheet

Executive Summary

Asthma drug Singulair (montelukast sodium) receives FDA approval for seasonal allergic rhinitis (hay fever) indication Dec. 31, Merck says. Available by prescription in 10 mg tablets for adults, 4 mg and 5 mg chewable tablets for children two to 14, as well as 4 mg oral granules, the product joins the dynamic allergy relief market now adjusting to OTC availability of loratadine (Claritin, Alavert). Merck says it currently has no plans to switch Singulair OTC...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS094977

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel